Introduction {#Sec1}
============

*NR0B1* and its protein product DAX1 are expressed in the hypothalamic--pituitary--adrenal/gonadal axis, and mutations in the gene encoding this transcription factor result in adrenal hypoplasia congenital and hypogonadotropic hypogonadism (Guo et al. [@CR7]; Ikeda et al. [@CR8]). Zhao et al. ([@CR17]) recently identified and described the spatial and temporal expression patterns of the zebrafish ortholog *dax1*. These in situ hybridization (ISH) studies on zebrafish embryos revealed *dax1* expression in a bilateral structure cephalad and medial to the pectoral fins in the region of the 5th branchial arch, appearing around 26 h postfertilization (hpf), peaking about 32 hpf, and nearly lost by 72 hpf. The 5th branchial arch and its association with tooth development in the zebrafish model have been well characterized in numerous other studies (Jackman et al. [@CR9]; Van der Heyden et al. [@CR15]). ISH with *dax1* and previously identified tooth markers colocalized these mRNAs to the area of pharyngeal tooth development. The association of *dax1* and the 5th branchial arch prompted us to search for a possible link between zebrafish tooth development and this orphan nuclear receptor.

*Pitx2*, a DNA- and RNA-binding homeodomain protein, is responsible for normal heart morphogenesis, mandibular and maxillary development, and normal pituitary and tooth development (Cox et al. [@CR4]). There are three major isoforms found in human, mouse, chicken, frog, and zebrafish. *pitx2a*, until this report, was the earliest known marker of tooth development in zebrafish (Jackman et al. [@CR9]). The gene begins expression at 36 hpf and is found in all developing teeth. No previously known tooth marker has been shown to be expressed in zebrafish before *pitx2a*. *lhx6* is expressed in the mesenchyme of the developing tooth germ as early as 28 hpf; however, the role of this gene in tooth development is unclear (Jackman et al. [@CR9]). Previous double ISH showed *pitx2a* and *dax1* to have adjacent expression (Zhao et al. [@CR17]), suggesting a possible role for *dax1* in tooth development.

The role of the *Dlx*/*dlx* family of genes is well described in mouse and zebrafish (Borday-Birraux et al. [@CR3]; Zhao et al. [@CR18]), and mutations in this gene family are known to cause severe disorders in human dentition (Green et al. [@CR6]). *Dlx2* is the earliest known tooth marker in mice (Thomas et al. [@CR14]). Double ISH of *dlx2a* and *dlx2b* with *dax1* shows adjacent expression in the region of the 5th branchial arch in zebrafish (Zhao et al. [@CR18], doctoral thesis). *Pitx*2 and *Dlx2* are expressed in the same tissues in early development. Green et al. ([@CR6]) recently described the function of *Pitx2* as an upstream regulator of *Dlx2* expression. Since *Pitx2* is known to be an upstream regulator of *Dlx2* activity and *dax1* and *pitx2a* do not appear to be closely related developmentally, it is unlikely that *dax1* affects expression of *dlx2*a or *dlx2b*.

*eve1* is the closest paralog to the *even-skipped-related* (*evx*) class of genes, which are homeodomain-containing transcription factors with varying expression patterns in different species (Laurenti et al. [@CR10]). The zebrafish genome contains three *evx* genes, *evx1*, *evx2*, and *eve1*. In zebrafish, *evx1* and *evx2* are responsible for anterior--posterior axis formation (Avaron et al. [@CR1]). The human genome contains paralogs for only two of these genes, *EVX1* and *EVX2*. There is no known ortholog to *eve1* in mammals. Laurenti et al. ([@CR10]) recently discovered that the gene *eve1* is expressed in the placode of the first primary tooth, 4V^1^, in zebrafish, suggesting it may be involved in early tooth initiation (Laurenti et al. [@CR10]). *eve1* is not expressed in early odontogenesis, like *pitx2* and *dlx2* isoforms, but expressed at 48 hpf and is restricted only to initiation of the first tooth and early differentiation of ameloblasts, the enamel organ precursor. The *EVX* gene family has not been previously shown to be involved in mammalian tooth development. Single ISH of *eve1* in zebrafish embryos showed a paired structure near the 5th branchial arch, similar to the expression pattern seen with *dax1*.

The proximity of the expression of *dax1* to 5th branchial arch and numerous known tooth markers led us to hypothesize that *dax1* is involved in pharyngeal tooth development in the zebrafish.

Materials and methods {#Sec2}
=====================

Wild-type zebrafish (AB, Tübingen, or SS) were maintained at 28.5°C. Embryos were obtained by natural spawning and cultured following standard described procedures (Westerfield [@CR16]). Of phenylthiourea (Sigma), 0.03% was added to the culture medium at approximately 6 hpf to inhibit pigment formation.

cDNA transformation {#Sec3}
-------------------

**Constructs used** cDNA construct for *dax1* was isolated by Dr. Yan Zhao from the sequence from the Sanger Centre zebrafish genome database (<http://www.sanger.ac.uk/Projects/D_rerio/>; Zhao et al. [@CR17]).

The following cDNA/expressed sequence tag (EST) constructs were purchased from Open Biosystems (<http://www.openbiosystems.com/>) based on their accession numbers. The gene sequence was obtained from The Zebrafish Information Network ([www.zfin.org](http://www.zfin.org)) and a Basic Local Alignment Search Tool alignment of the gene of interest and available constructs was performed to confirm the identity: *dlx2b:* Catalog \# MDR1738-8985435; Vector name: pBluescript SK+*pitx2a:* Catalog \# EDR1052-7472648; Vector name: pExpress-1

The following ESTs were purchased from the Zebrafish International Resource Center (<http://zebrafish.org/zirc/home/guide.php>): *dlx2a*: Catalog \# ZDB-EST-051103-34; Vector name: pSportI*eve1*: Catalog \# ZBD-EST-cb872; Vector name: pBSII-SK+

*eve1* and *dlx2a* were transformed according to the protocol as supplied by Stratagene. DNA was isolated using the Mini-Prep Kit and protocol as supplied by Qiagen. The constructs were linearized by restriction enzyme digestion and the products were purified using a Gel Extraction Kit (Bioland).

Probe synthesis for whole-mount in situ hybridization {#Sec4}
-----------------------------------------------------

rNPT mix consists of 20 μl 10 mM ATP, 20 μl 10 mM GTP, 20 μl 10 mM CTP, 13 µl 10 mM UTP, and 7 μl 10 mM digoxigenin-11-UTP (Boehringer Mannheim). The reaction components for probe synthesis for *dax1*, *eve1*, *pitx2a*, *dlx2a*, and *dlx2b* were set up as follows: 500-ng linearized DNA template, 5 µl 5× transcription buffer (Promega), 5 μl rNPT mix, 2.5 µl 100 mM dithiothreitol (Promega), 1.0 µl RNasin (Promega), 1.0 µl RNA polymerase (Promega), and nuclease-free water (Ambion) to 25 µl total volume. Probe synthesis was carried out according to standard described procedure (Darby and Hewitson [@CR5]).

Whole-mount in situ hybridization {#Sec5}
---------------------------------

Solutions: Hyb−: 50% formamide, 5× standard sodium citrate (SSC), 0.1% Tween-20hyb+: hyb−, 500 μg/ml torula yeast RNA, 500 μg/ml heparinMaleic acid buffer: 100 mM maleic acid (Sigma M0375), 150 mM NaCl, pH 7.5Re-equilibration buffer: 100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl~2~, Tris-HCl, pH 9.5

Embryos were collected at various stages of development, dechorionated by pronase treatment (2 mg/ml, 3--10 min at room temperature), fixed with 4% paraformaldehyde diluted in 1× phosphate buffered saline (PBS), and allowed to incubate for at least 2 h at room temperature or overnight at 4°C. The embryos were dehydrated in sequential steps for 5 min at room temperature as follows: 25% methanol/75% PBS plus Tween-20 (PBST), 50% methanol/50% PBST, 75% methanol/25% PBST, and 100% methanol. The embryos were placed at −20°C at least overnight prior to use. When ready for ISH, the embryos were sequentially rehydrated for 5 min at room temperature in each of the following: 75% methanol/25% PBST, 50% methanol/50% PBST, 25% methanol/75% PBST, and 100% PBST. Single and double ISH studies were performed according to the protocol outlined by Darby and Hewitson ([@CR5]).

Morpholino injection {#Sec6}
--------------------

Danieau's solution consists of 58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO~4~, 0.6 mM Ca(NO~3~)~2~, and 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.6)

Sequences: *dax1* Morpholino (MO) 2: 5′-CAGAGCTGCTTATGTTTCGTTGCTG-3′*dax1* Morpholino 3: 5′-CTGAGCTGCACGCTTGCACATGATC-3′*dax1* mismatch control (mMO): 5′-CAcAGgTGCTTATcTTTCcTTGgTG-3′

Morpholinos were synthesized and purchased from Gene Tools (<http://www.gene-tools.com/>). A stock solution of 10 μg/μl was prepared by dissolving the lyophilized powder in doubly distilled water. The stock solution was diluted to a working concentration of 2 μg/μl in 1× Danieau's solution. Freshly laid embryos were collected and placed into embryo culture medium (brackish water) and transferred onto an agarose platform. Ten nanograms of MO2, MO3, or mMO solution was injected in the yolk of one- to two-cell embryos, or four- to eight-cell embryos, from the vegetal pole. Microinjection was performed using a Nanoject injector.

Deparaffinization and ISH on human tissue samples {#Sec7}
-------------------------------------------------

Solutions: Denhardt's solution 100× stock: distilled H~2~O 500 ml total volume, Ficoll 10 g, polyvinylpyrrolidone 10 g, bovine serum albumin 10 gHybridization buffer: distilled H~2~O 200 ml total volume, formamide 100 ml, dextran sulfate 20 g, SSC (20 stock) 40 ml, Denhardt's solution (100×) 5 ml, salmon sperm DNA 0.05 g, yeast transfer RNA 0.12 g, SDDS 0.05 g, Dig-block reagent 0.2 g

After obtaining institutional review board exemption, we obtained 5-μm-thick formalin-fixed, paraffin-embedded human tissue samples of normal adrenal gland, normal dental tissue, benign ameloblastoma tumor, and malignant ameloblastoma tumor cut from previously excised tissue using steel microtome blade from the UCLA Tissue Core and Pathology Laboratory. The tissue sections were deparaffinized according to standard described protocol (Abcam). ISH was then performed according to the protocol provided by Roche Applied Science.

Results {#Sec8}
=======

ISH using digoxigenin-labeled antisense riboprobes for *pitx2a* showed that its expression pattern remained identical in *dax1* MO2- and *dax1* MO3-injected embryos compared to control embryos at all studied stages of development (Fig. [1](#Fig1){ref-type="fig"}). These data suggest that *dax1* is not an upstream regulator of *pitx2a* expression. Fig. 1Single ISH of *pitx2a* at 48 hpf. **a** Wild-type control embryo showing expression of *pitx2a* in the developing brain and 5th branchial arch where pharyngeal tooth development occurs. **b***dax1* MO2-injected embryo showing unchanged expression of *pitx2a*. *dax1* MO3-injected embryos showed a similar unchanged *pitx2a* expression pattern

Since *Pitx2a* is a known upstream regulator of the *Dlx* isoforms and since our results showed that *dax1* is not an upstream regulator of *pitx2a*, we hypothesized that *dax1* MO should have no effect on the expression patterns of *dlx2a* and *dlx2b*. ISH confirmed our hypothesis by showing no difference in expression of *dlx2a* or *dlx2b* on embryos injected with *dax1* MO2 or *dax1* MO3 compared to the uninjected control embryos (results not shown).

Double ISH studies of *eve1* and *dax1* showed colocalization of expression in the region of the 5th branchial arch starting at 48 hpf (Fig. [2](#Fig2){ref-type="fig"}). Double ISH of *eve1* and *dax1* at 60 and 72 hpf showed similar results (results not shown). ISH studies showed complete lack of expression of *eve1* in the majority of *dax1* MO2- and *dax1* MO3-injected embryos compared to the control mismatch MO-injected embryos at 48 hpf (Fig. [3](#Fig3){ref-type="fig"}). Again, similar results were also seen at 60 and 72 hpf, respectively (results not shown). When the embryos were injected before or during the two-cell stage, nearly all the MO-injected embryos showed complete lack of *eve1* expression. However, when we injected embryos in the four- to eight-cell stage, when the MO does not disperse evenly between developing cells to inhibit expression, there was no statistically significant difference in the expression between the MO-injected and mismatch MO-injected embryos (Table [1](#Tab1){ref-type="table"}). Fig. 2Double ISH of *dax1* and *eve1.* The *upper arrow* shows purple-staining *eve1* expression while the *bottom arrow* shows red-staining *dax1*Fig. 3ISH of *eve1* on 48-hpf embryos. **a***Arrow* shows *eve1* in the 5th branchial arch in control wild-type embryo. **b***Circle* shows absence of *eve1* expression in a *dax1* MO-injected wild-type embryoTable 1A statistically significant difference in the number of embryos exhibiting expression of *eve1* in mismatch MO-injected embryos as compared to *dax1* MO2- and *dax1* MO3-injected embryosWhen embryos are injected early in embryogenesis, e.g., one- to two-cell stage, the MO disperses evenly between the cells inhibiting translation of the target mRNA. Injection later in embryogenesis, e.g., more than four-cell stage, does not allow for even dispersion of MO resulting in incomplete inhibition of translation*Ctr* mismatch MO

Although no ortholog for *eve1* exists in humans, we hypothesized that *DAX1* may be involved in primary tooth development and amelogenesis. ISH studies with *DAX1* on normal human dental tissue and benign and malignant ameloblastoma tumors were performed. Normal dental tissue showed weak expression of *DAX1* in the dental epithelium (Fig. [4a](#Fig4){ref-type="fig"}), while benign and malignant ameloblastoma tumors showed strong expression of *DAX1* in the clusters of ameloblasts, with higher expression in malignant tumor tissue (Fig. [4b, c](#Fig4){ref-type="fig"}) Fig. 4ISH of *DAX1* on human dental tissue specimens. **a** Normal dental epithelium with the developing enamel organ. *Arrows* indicate ameloblasts. **b** Benign ameloblastoma tumor. *Arrows* indicate purple-stained ameloblasts expressing *DAX1*. **c** Malignant ameloblastoma tumor with numerous clusters of purple-stained ameloblasts infiltrating normal dental tissue.

Discussion {#Sec9}
==========

Here, we illustrate another possible novel function of *nr0b1* as the earliest marker of zebrafish tooth development. Its expression in the 5th branchial arch 10 h earlier in embryogenesis compared to the previously described *pitx2a*, appearing around 36 hpf, and 22 h earlier than *eve1* suggests that it may be involved in the regulation of tooth development and amelogenesis. This difference is remarkable, considering that zebrafish embryogenesis is complete by 72 h. It is yet to be determined why *dax1* expression occurs so early in this region as the primary tooth in zebrafish does not start to form until 36 hpf or appear until 48 hpf. This may speak to the complexity of gene product interactions required to initiate and to continue tooth development in this polyphyodont model.

It remains to be shown whether tooth development occurs in *dax1* MO-injected embryos. It also remains to be shown if *dax1* and *eve1* expression occurs in the same versus adjacent cells. Laurenti et al. ([@CR10]) showed *eve1* expression in the placode of the first developing tooth at 48 hpf followed by limited expression in differentiating ameloblasts in zebrafish at 72 hpf. Human tissue sections show *DAX1* expression in ameloblasts in normal dental tissue and ameloblastoma tumor cells.

The expression pattern of *dax1* in zebrafish, including the expression of *dax1* in the 5th branchial arch, has been well described by numerous previous authors (Bertrand et al. [@CR2]; Thisse and Thisse [@CR13]; Zhao et al. [@CR17]). None of the previous studies identified a role of *dax1* expression in developing cartilage. Lack of evidence from previous studies of *dax1* involvement in cartilage formation or differentiation supports our inference that *dax1* is likely involve in tooth formation, the only know function of the 5th branchial arch in zebrafish, as opposed to cartilage involvement and that *eve1* and *dax1* expression occurs in the same cells.

Numerous previous studies have identified functions of *NR0B1* outside the HPAG axis. Niakan et al. ([@CR12]) showed in the mouse model that *Dax1* plays a role in maintaining early embryonic stem cells in a less-differentiated state. Mendiola et al. ([@CR11]) showed that *DAX1* is upregulated by the EWS/FLI1 oncoprotein in Ewing sarcoma tumors. *DAX1* expression in normal human teeth as well as ameloblastoma tumors was a previously unidentified association of this dynamic gene product. The use of the zebrafish model vertebrate has allowed us to elucidate not only a possible gene function that had gone unnoticed but also a marker for the most common odontogenic tumor, the ameloblastoma.
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